Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors
This is a multicenter, open, dose escalation, single and multiple administration phase Ⅰ/Ⅱ clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and primary clinical efficacy of LY01616 in patients with advanced solid tumors
Advanced Solid Tumors
DRUG: LY010616
Incidence and severity of adverse events (AEs) ., From the initiation of study treatment to the completion of safety follow-up after the end of study treatment, up to 2 years.
Area under the curve (AUC) of LY01616, up to cycle 6nd (cycle 1st is 21 days, the other cycles are 14 days)|Maximum Concentration (Cmax) of LY01616, up to cycle 6nd (cycle 1st is 21 days, the other cycles are 14 days)|Time of maximum concentration (Tmax) of LY01616, up to cycle 6nd (cycle 1st is 21 days, the other cycles are 14 days)|Objective response rate (ORR), up to 2 years|Disease control rate (DCR), up to 2 years|Progression-free survival (PFS), up to 2 years|Overall survival (OS);, up to 2 years|Duration of remission (DoR), up to 2 years
This is a multicenter, open, dose escalation, single and multiple administration phase Ⅰ/Ⅱ clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and primary clinical efficacy of LY01616 in patients with advanced solid tumors